SCHEMBL2858017

SCHEMBL2858017

CS(=O)(=O)Nc1cccc(C(N)=O)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
POLB P06746 1/20 0.69
HPGD P15428 1/20 0.56
ATIC P31939 1/20 0.56
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
PARP1 P09874 8/20 0.51
PARP10 Q53GL7 6/20 0.51
PARP14 Q460N5 3/20 0.51
CHUK O15111 2/20 0.51
IKBKB O14920 1/20 0.51
HTT P42858 1/20 0.50
KEAP1 Q14145 1/20 0.50
INSR P06213 1/20 0.49
MAPK8 P45983 1/20 0.49
CAMKK2 Q96RR4 1/20 0.49
PARP15 Q460N3 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29522198 0.84 ALDH1A1 (0.75) ALDH1A1SMN1; SMN2POLBHPGDMEN1
SCHEMBL334530 0.84 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2POLBHPGDMEN1
SCHEMBL1677059 0.84 ALDH1A1 (0.75) ALDH1A1SMN1; SMN2POLBHPGDMEN1
SCHEMBL29398556 0.83 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2POLBHPGDMEN1
SCHEMBL27889372 0.83 CHUK (0.61) ALDH1A1SMN1; SMN2POLBCHUKIKBKB
SCHEMBL4509115 0.83 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2POLBHPGDCA1
SCHEMBL8008330 0.83 SMN1; SMN2 (0.73) ALDH1A1SMN1; SMN2POLBHPGDCA1
SCHEMBL6840090 0.82 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2POLBHPGDCA1
SCHEMBL14973118 0.82 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2POLBHPGDATIC
SCHEMBL11705518 0.81 CA1 (0.71) ALDH1A1SMN1; SMN2POLBHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP claimed
EP-1937652-B1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMA INC (US) 2014-07-30 EP claimed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US claimed
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 US claimed
EP-2340021-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2012-11-07 EP claimed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO claimed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
US-20260014133-A1 SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN ST JUDES CHIDRENS RES HOSPITAL INC (US) 2026-01-15 US disclosed
WO-2025217141-A1 PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 ENANTA PHARMACEUTICALS, INC. (US) 2025-10-16 WO disclosed
US-4223133-A USING A TRIARYL PHOSPHITE-HALOGEN COMPLEX ELI LILLY AND COMPANY (US) 1980-09-16 US disclosed
EP-0014567-A1 Processes for preparation of beta-lactam compounds ELI LILLY AND COMPANY (US) 1980-08-20 EP disclosed
US-4211702-A TRIARYLPHOSPHITE-HALOGEN COMPLEX HALOGENATING AGENT ELI LILLY AND COMPANY (US) 1980-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885SMN1; SMN2 2109/4885POLB 883/4885
US-20260014133-A1 SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN CRBN, CDR2, CLNS1A ALDH1A1 3557/4885SMN1; SMN2 507/4885POLB 4129/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885SMN1; SMN2 2109/4885POLB 883/4885
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS ALDH1A1 1038/4885SMN1; SMN2 3473/4885POLB 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.